相关临床试验
17
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
14
82.3%
尚未招募
1
5.9%
招募中
1
5.9%
终止
1
5.9%
暂无批准数据
- The 2026 Scientists' Choice Awards were announced at the ADLM Clinical Lab Expo, recognizing the most impactful clinical diagnostics innovations of 2025. - Thermo Fisher Scientific's Oncomine Dx Express Test won Best New Clinical Diagnostics Kit or Assay for advancing precision diagnostics and delivering timely, actionable results. - Mindray's FA-N Series Fully Automated Microbial Culture System won Best New Clinical Diagnostics Instrumentation for enhancing microbiology workflow productivity and operational efficiency. - Siemens Healthineers won Clinical CE Webinar of the Year, while Danaher received the Innovation in Thought Leadership award for educational content and industry insights.
- The global laboratory robotics market was valued at USD 2.73 billion in 2025 and is projected to reach USD 5.12 billion by 2034, growing at a CAGR of 7.22%. - North America holds the largest market share at 41%, with more than 52% of large U.S. pharmaceutical laboratories already utilizing robotic automation systems. - Drug discovery applications account for nearly 49% of market share, while automated liquid handling robots represent approximately 63% of product segment revenue. - AI-enabled robotic platforms, cloud-connected systems, and precision medicine initiatives are key trends accelerating adoption across pharmaceutical and biotechnology sectors.
- The global molecular diagnostics market is projected to grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6%, according to MarketsandMarkets. - PCR and real-time PCR technologies dominate the market with a 42.54% revenue share, while sequencing-based testing is the fastest-growing segment due to personalized medicine adoption. - North America leads the global market with a 38.49% share, while Asia Pacific is the fastest-growing region with an estimated CAGR of 24.45% through 2035. - Key players including Roche, Danaher, Abbott, and Thermo Fisher are investing in automation, AI-powered analytics, and multiplex assay development to strengthen competitive positioning.
- bioMérieux, a global in vitro diagnostics leader, has acquired 100% of Accellix for approximately €35 million to enhance its cell and gene therapy quality control capabilities. - Accellix's compact flow cytometry platform delivers quality control results in under 30 minutes, enabling real-time monitoring during cell therapy manufacturing processes. - The acquisition completes bioMérieux's comprehensive offering for cell and gene therapies by adding cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing portfolio. - Recent analyses indicate cell and gene therapies achieve clinical success rates two to three times higher than traditional treatments, highlighting the growing importance of rigorous quality control frameworks.
- Virax Biolabs has appointed Iain Miller, PhD as an Independent Director, bringing over 30 years of diagnostics and MedTech leadership experience to guide the company's strategic development. - Dr. Miller previously led Presymptom Health and developed InfectiClear®, a novel diagnostic for infectious diseases, while serving on regulatory committees including UK's NICE Technology Appraisal Committee. - The appointment comes as Virax works to expand its immune profiling platform from Research-Use-Only products toward IVD development and regulatory approval for monitoring chronic and post-viral conditions.
- bioMérieux has received FDA 510(k) clearance for its VITEK COMPACT PRO system, designed to improve microorganism identification and antibiotic susceptibility testing in clinical and industrial laboratories. - The new system features ergonomic design improvements and simplified workflow that reduce sample processing time while maintaining the accuracy and reliability of its predecessor, the VITEK 2 COMPACT. - With antimicrobial resistance causing 1.3 million deaths annually, the VITEK COMPACT PRO aims to provide faster diagnostic results to optimize patient treatment and support antimicrobial stewardship programs worldwide.
- bioMérieux's BIOFIRE FILMARRAY Tropical Fever Panel has received FDA 510(k) clearance, enabling rapid identification of pathogens causing tropical fevers. - The PCR test swiftly detects pathogens like Plasmodium species, crucial for malaria treatment, and aids in reducing inappropriate antibiotic use. - Scheduled for commercial launch in early 2025, the test promises improved patient management and public health diagnostics through timely diagnosis. - Developed in collaboration with U.S. agencies, the panel underscores the importance of public-private partnerships in advancing health innovation.
- Oxford Nanopore and the UK Government have formed a strategic partnership to implement a real-time pathogen surveillance system across 30 NHS sites, aiming to strengthen national biosecurity. - The collaboration extends beyond surveillance to include advancing genomic medicine, improving NHS patient care through genomic discoveries, and boosting economic growth in life sciences. - The initiative builds upon recent NHS genomic programs, including a newborn screening study for 200 rare genetic diseases, with support from UK Biobank and Genomics England.
